Vaxzevria针对Omicron变体,取得初步积极数据

2022-01-16 Allan MedSci原创

近日,阿斯利康 (AstraZeneca) 报告了其疫苗Vaxzevria针对Omicron变体的试验数据。

近日,阿斯利康 (AstraZeneca) 报告了其疫苗Vaxzevria针对Omicron变体的试验数据。

据路透社报道,免疫原性和安全性试验D7220C00001的结果显示,该疫苗对Omicron变体以及其他变体(包括 Beta、Delta、Alpha 和 Gamma)产生了更高的抗体反应。

阿斯利康报告说,以前接种过Vaxzevria或mRNA疫苗的人的反应有所增加。他们补充说,鉴于当前对加强剂量的需求,他们将向全球监管机构提交这些数据。

阿斯利康与牛津大学的研究人员一起开发了Vaxzevria,实验室研究上个月发现,三剂Vaxzevria对 Omicron有效。

Vaxzevria由一种病毒(腺病毒)组成,该病毒已被修饰以包含制造SARS-CoV-2病毒的基因。一旦被注射,疫苗就会将SARS-CoV-2基因输送到细胞中,进入体内。细胞将使用该基因产生刺突蛋白。然后,个体的免疫系统会将这种蛋白质识别为外来蛋白质,并产生抗体作为回应,激活T细胞对其进行攻击。

2021年12月,英国的一项重大试验发现,阿斯利康的疫苗在使用其自己的疫苗或基于mRNA技术的疫苗进行初始疫苗接种后作为加强剂给予时会增加抗体水平。尽管如此,该研究得出的结论是,辉瑞和Moderna制造的mRNA疫苗在加强剂量时对抗体的促进作用最大。牛津疫苗集团负责人Andrew Pollard评论道:“这些重要的研究表明,在接种两次初始剂量的相同疫苗之后,或在mRNA或灭活疫苗之后,第三剂Vaxzevria可以强烈增强对COVID-19的免疫力”。

 

原始出处:

https://www.pharmatimes.com/news/new_study_finds_astrazeneca_booster_generates_higher_antibodies_against_omicron_1386196

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2084689, encodeId=500720846890d, content=<a href='/topic/show?id=61f411e013b' target=_blank style='color:#2F92EE;'>#Micro#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11701, encryptionId=61f411e013b, topicName=Micro)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d59291, createdName=xjy02, createdTime=Mon Jul 11 13:55:59 CST 2022, time=2022-07-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1857996, encodeId=6539185e99657, content=<a href='/topic/show?id=3f48525849' target=_blank style='color:#2F92EE;'>#CRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5258, encryptionId=3f48525849, topicName=CRO)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c30265, createdName=jiafufeng@yaho, createdTime=Thu Jul 07 02:55:59 CST 2022, time=2022-07-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1803245, encodeId=19a0180324552, content=<a href='/topic/show?id=7ef0e51191e' target=_blank style='color:#2F92EE;'>#积极数据#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75119, encryptionId=7ef0e51191e, topicName=积极数据)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTK17mLkWpia3T92NlEWTkEhrhZa7XPNic2JqQumEicZXGYFG6Ww5SCIl0Uq62bhhPnibAqIZDHtRva92A/132, createdBy=e0752500025, createdName=江川靖瑶, createdTime=Sat Feb 12 18:55:59 CST 2022, time=2022-02-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1186733, encodeId=289f1186e332b, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3818101931, createdName=wjl066452, createdTime=Fri Jan 21 10:15:43 CST 2022, time=2022-01-21, status=1, ipAttribution=)]
    2022-07-11 xjy02
  2. [GetPortalCommentsPageByObjectIdResponse(id=2084689, encodeId=500720846890d, content=<a href='/topic/show?id=61f411e013b' target=_blank style='color:#2F92EE;'>#Micro#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11701, encryptionId=61f411e013b, topicName=Micro)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d59291, createdName=xjy02, createdTime=Mon Jul 11 13:55:59 CST 2022, time=2022-07-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1857996, encodeId=6539185e99657, content=<a href='/topic/show?id=3f48525849' target=_blank style='color:#2F92EE;'>#CRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5258, encryptionId=3f48525849, topicName=CRO)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c30265, createdName=jiafufeng@yaho, createdTime=Thu Jul 07 02:55:59 CST 2022, time=2022-07-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1803245, encodeId=19a0180324552, content=<a href='/topic/show?id=7ef0e51191e' target=_blank style='color:#2F92EE;'>#积极数据#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75119, encryptionId=7ef0e51191e, topicName=积极数据)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTK17mLkWpia3T92NlEWTkEhrhZa7XPNic2JqQumEicZXGYFG6Ww5SCIl0Uq62bhhPnibAqIZDHtRva92A/132, createdBy=e0752500025, createdName=江川靖瑶, createdTime=Sat Feb 12 18:55:59 CST 2022, time=2022-02-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1186733, encodeId=289f1186e332b, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3818101931, createdName=wjl066452, createdTime=Fri Jan 21 10:15:43 CST 2022, time=2022-01-21, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=2084689, encodeId=500720846890d, content=<a href='/topic/show?id=61f411e013b' target=_blank style='color:#2F92EE;'>#Micro#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11701, encryptionId=61f411e013b, topicName=Micro)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d59291, createdName=xjy02, createdTime=Mon Jul 11 13:55:59 CST 2022, time=2022-07-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1857996, encodeId=6539185e99657, content=<a href='/topic/show?id=3f48525849' target=_blank style='color:#2F92EE;'>#CRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5258, encryptionId=3f48525849, topicName=CRO)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c30265, createdName=jiafufeng@yaho, createdTime=Thu Jul 07 02:55:59 CST 2022, time=2022-07-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1803245, encodeId=19a0180324552, content=<a href='/topic/show?id=7ef0e51191e' target=_blank style='color:#2F92EE;'>#积极数据#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75119, encryptionId=7ef0e51191e, topicName=积极数据)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTK17mLkWpia3T92NlEWTkEhrhZa7XPNic2JqQumEicZXGYFG6Ww5SCIl0Uq62bhhPnibAqIZDHtRva92A/132, createdBy=e0752500025, createdName=江川靖瑶, createdTime=Sat Feb 12 18:55:59 CST 2022, time=2022-02-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1186733, encodeId=289f1186e332b, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3818101931, createdName=wjl066452, createdTime=Fri Jan 21 10:15:43 CST 2022, time=2022-01-21, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=2084689, encodeId=500720846890d, content=<a href='/topic/show?id=61f411e013b' target=_blank style='color:#2F92EE;'>#Micro#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11701, encryptionId=61f411e013b, topicName=Micro)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d59291, createdName=xjy02, createdTime=Mon Jul 11 13:55:59 CST 2022, time=2022-07-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1857996, encodeId=6539185e99657, content=<a href='/topic/show?id=3f48525849' target=_blank style='color:#2F92EE;'>#CRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5258, encryptionId=3f48525849, topicName=CRO)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c30265, createdName=jiafufeng@yaho, createdTime=Thu Jul 07 02:55:59 CST 2022, time=2022-07-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1803245, encodeId=19a0180324552, content=<a href='/topic/show?id=7ef0e51191e' target=_blank style='color:#2F92EE;'>#积极数据#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75119, encryptionId=7ef0e51191e, topicName=积极数据)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTK17mLkWpia3T92NlEWTkEhrhZa7XPNic2JqQumEicZXGYFG6Ww5SCIl0Uq62bhhPnibAqIZDHtRva92A/132, createdBy=e0752500025, createdName=江川靖瑶, createdTime=Sat Feb 12 18:55:59 CST 2022, time=2022-02-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1186733, encodeId=289f1186e332b, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3818101931, createdName=wjl066452, createdTime=Fri Jan 21 10:15:43 CST 2022, time=2022-01-21, status=1, ipAttribution=)]
    2022-01-21 wjl066452

    学习

    0

相关资讯

最后一个寒冬!尽管Omicron更具传染性,但攻击性大大降低了

随着新冠病毒的大规模流行,新的病毒突变株不断出现,Alpha、Beta、Gamma、Delta、Omicron等,其中一些突变株具有更强的感染能力或更强免疫逃逸能力。

Moderna表示Spikevax加强针可触发对Omicron的更高保护

与加强前相比,额外注射100μg剂量水平的 Spikevax 可使抗体水平上升 83 倍。

阿斯利康和Novavax表示他们的疫苗对Omicron有效

Omicron 现在是美国的主要变体,并且在西欧大部分地区迅速成为主导变体。在英国,Omicron 已导致每日感染人数飙升至 100,000 以上。

拓展阅读

Neurology:感染Omicron住院COVID-19患者的神经系统疾病的发生率和长期功能结局

COVID-19相关的神经系统疾病的发生率在大流行病的预接种阶段有所下降。

Emerg Microbes Infect:COVID-19灭活疫苗对SARS-CoV-2 Omicron变体感染者中轻度疾病、肺炎和重症疾病的有效性

与原始Delta (B.1.617.2)变体相比,接种疫苗的个体对Omicron变体的中和抗体反应大大降低,尽管加强针增加了对Omicron变体的反应。

Infect Dis Ther:Paxlovid治疗老年人2019-冠状病毒Omicron变异株的安全性和有效性

omicron变异感染患者的住院率、住院时间、死亡率均较其他变异感染患者有所下降,且症状较轻。

NEJM:林丹瑜团队证实,二价mRNA疫苗加强针在预防Omicron的住院和死亡方面更有效

在预防重症和死亡方面,二价mRNA新冠疫苗作为加强针效果好于单价mRNA新冠疫苗作为加强针。

上海交大团队发现,重复接种灭活疫苗,会减弱突破性感染后对Omicron的中和抗体活性

一些研究显示,接种三剂新冠疫苗比接种两剂对Omicron具有更好的中和活性,但尚不清楚接种疫苗后的突破性感染,对接种三剂和接种两剂疫苗的人的免疫反应有何影响。

STTT:上海大学陈亮/空军军医大学朱平/边惠洁等合作发现Omicron变异株感染的免疫学和代谢特征

该研究报道了Omicron变异株感染的免疫学和代谢特征。该研究系统地研究了Omicron变异感染的免疫和代谢特征。